Emulsome-Based Delivery Strategies: The Practical, Data-Backed Guide

Emulsomes are tiny lipid carriers with a solid core and phospholipid shell, designed to load hydrophobic drugs and release them in a controlled way. Because they improve solubility and stability, emulsomes can raise exposure in target tissues like the liver and spleen. At Creative Biolabs, we design and optimize emulsomes so your research gains reliable performance across IV, oral, pulmonary, and topical routes.

Introduction to Emulsomes

Definition

Emulsomes are advanced lipid-based nanocarriers that blend the advantages of liposomes and solid lipid nanoparticles, emerging as a practical, data-backed solution for overcoming drug delivery challenges. Defined as ultra-deformable vesicular systems, they feature a solid lipid core (solid at 25°C, transitioning to liquid near physiological temperature) encapsulated by a phospholipid bilayer, thereby enabling dual loading of hydrophilic and lipophilic drugs (Figure 1).

Fig.1 The emulsome structure.³

The functionality and versatility of emulsomes stem from their precisely designed, multi-component structure—each element serving a critical role in drug encapsulation, stability, and delivery efficacy.

Composition

The functionality and versatility of emulsomes stem from their precisely designed, multi-component structure—each element serving a critical role in drug encapsulation, stability, and delivery efficacy.

The Solid Lipid Core

The innermost core is the foundational drug-loading region, composed of triglycerides (e.g., tristearin, tripalmitin, trilaurin) that are solid at room temperature (25°C) but transition to a liquid near physiological temperature (~37°C). This solid-to-liquid shift enables controlled release of encapsulated drugs. Triglycerides are selected for their low hydrophilic-lipophilic balance (HLB, ideal for sustained release) and unbranched fatty acid chains (C10-C18), which minimize emulsion degradation during storage. The core exclusively traps lipophilic drugs (e.g., curcumin, amphotericin B) via hydrophobic interactions, resolving solubility challenges for poorly water-soluble actives.

The Phospholipid Bilayer

Surrounding the lipid core is a multilamellar phospholipid bilayer—the system’s "structural and hydrophilic drug-loading layer." Key components include natural or hydrogenated phospholipids such as soy lecithin (rich in phosphatidylcholine) or phosphatidylcholine itself. Phosphatidylcholine’s amphipathic nature (hydrophilic head, hydrophobic tail) forms stable bilayers, with aqueous compartments between layers for encapsulating hydrophilic drugs (e.g., vinpocetine, oxcarbazepine). The bilayer also enhances biocompatibility (mimicking biological membranes) and controls in vivo behavior—regulating circulation half-life and tissue targeting by adjusting its surface properties.

Cholesterol

Cholesterol is an essential stabilizer, integrated into the phospholipid bilayer to optimize structural integrity and drug entrapment. It modifies the bilayer’s packing density: low-to-moderate concentrations can enhance the fluidity, prevent vesicle fusion, and boost entrapment efficiency (EE) by up to 30% (e.g., from 62% to 92% for methotrexate-loaded emulsomes). Excess cholesterol (>50% of bilayer mass) disrupts bilayer regularity, however, causing drug leakage and reduced EE—making precise concentration control critical.

Negatively Charged Lipids

To improve colloidal stability, negatively charged lipids (e.g., oleic acid, phosphatidic acid, phosphatidylserine) are integrated into the bilayer to increase the emulsome’s zeta potential (typically to -20 to -30 mV). As a result, electrostatic repulsion between vesicles that prevents aggregation, flocculation, or coalescence is generated. For example, oleic acid incorporation can raise zeta potential from -12 mV to -28 mV, extending shelf-life by 3+ months. Additionally, the negative charge enhances aqueous compartment volume in the bilayer, further boosting hydrophilic drug loading capacity.

Antioxidants

Antioxidants are integrated to protect unsaturated lipids in the core/bilayer from oxidative degradation (e.g., peroxide formation). The most common choice is α-tocopherol (vitamin E) or butylated hydroxytoluene (BHT). For compatibility, the addition of 0.1-0.5% w/w α-tocopherol is preferred to avoid toxic byproducts. Antioxidants are unnecessary if the lipid core uses fully saturated triglycerides (e.g., tristearin), as saturated fats are resistant to oxidation.

Need a custom esmulsome formulation?

Partner with our experts at Creative Biolabs to design a system tailored to your research model.

How Emulsomes Work: Encapsulation, Stability, and Controlled Release

Emulsomes work through three linked, research-backed mechanisms that solve key drug delivery challenges:

Encapsulation

The solid triglyceride core (e.g., tristearin, tripalmitin) traps hydrophobic molecules (e.g., curcumin, amphotericin B) at high loadings (up to 50% w/w), far exceeding liposomes. Hydrophilic drugs are additionally entrapped in the phospholipid bilayer’s aqueous compartments, enabling dual-drug delivery.

Protection

The phospholipid shell (soy lecithin/phosphatidylcholine) acts as a barrier, shielding payloads from gastric pH, digestive enzymes, and oxidation—critical for oral/intranasal use (e.g., protecting vinpocetine from pre-systemic metabolism).

Controlled Release

Tuning the core’s lipid melting point (25-45°C), fatty acid chain length (C10-C18), and bilayer cholesterol ratio can slow the drug release, thus reducing the burst effects. For example, high-melting tristearin extends release to 24+ hours vs. liquid cores.

Pro tip:

Adjusting core lipids (e.g., trilaurin for faster release), bilayer phospholipid-cholesterol ratios, and processing temperature (e.g., 40°C for hot-method formulations) can shift release from hours to days, which is ideal when you want sustained exposures.

Emulsomes vs. Liposomes vs. Solid Lipid Nanoparticles (SLNs)

Emulsomes, liposomes, and SLNs are different types of lipid nanocarriers, of which each is tailored to specific delivery needs (Table 1). Emulsomes are excelling at loading hydrophobic drugs (e.g., amphotericin B) efficiently, with a 10-250 nm size enabling IV, oral, pulmonary, and topical use. Their release profile is sustained (~12-15% over 24 h), thereby reducing burst effects. Simultaneously, they boost solubility, protect payloads, and favor reticuloendothelial system (RES) distribution (liver/spleen). They are ideal carriers for antileishmanial, oncology, or anti-infective drugs. Liposomes, by contrast, consisting of aqueous cores and phospholipid bilayers, are mainly used for loading hydrophilic drugs. Compared with emulsomes, they suffer from short release (≤6 h) and high leakage. SLNs have solid lipid cores (no bilayer) for delivering lipophilic drugs. Although they offer stability, they lack dual-drug capacity. Therefore, by filling gaps where liposomes (short-acting) and SLNs (single-drug only) fall short, emulsomes stand out for balancing dual-drug potential, sustained release, and RES targeting.

Table 1 Comparison of transethosomes with liposomes and ethosomes.

When to Choose Emulsomes vs. Other Nanocarriers

Table 2 aligns with research showing emulsomes outperform others in bioavailability (e.g., 2x higher for vinpocetine vs. liposomes) and targeting efficiency.

• Choose emulsomes if you need: dual-drug delivery, prolonged release (e.g., intranasal brain targeting), or stability for oral/parenteral use.
• Pick liposomes for short-acting hydrophilic drugs (e.g., antibiotics).
• Opt for SLNs only if you are delivering single lipophilic drugs and prioritize low cost over versatility.

Table 2 Decision factors when choosing emulsomes.

Targeting the Reticuloendothelial System (RES): Liver and Spleen

As mentioned before, because of opsonization and particle size, emulsomes often show RES uptake, notably in the liver and spleen. This can be very helpful for:

• Leishmania-infected macrophages in the liver and spleen
• Liver-focused oncology payloads
• Hepatic infections and inflammation models

If you do not want RES targeting, you can adjust:

• PEGylation to reduce opsonization, thereby minimizing protein binding and extending circulation.
• Ligand grafting (e.g., folate, mannose, peptides, or antibodies) to direct receptors in other tissues.
• Particle size and surface charge to alter biodistribution, thereby improving circulation and certain cell interactions.

Note:

Always confirm that the ligand density does not destabilize the shell or reduce EE%.

Routes of Administration for Emulsome-Based Formulations

Because emulsomes range from 10 to 250 nm, they support several administration routes:

• Intravenous (IV): Direct access to circulation, with natural RES distribution.
• Oral / Intraduodenal: Potential lymphatic transport and first-pass avoidance; helpful for poorly soluble, lipophilic drugs.
• Pulmonary (Aerosol): Local lung exposure and possible systemic uptake through alveoli; particle engineering matters.
• Topical / Dermal: Local delivery with reduced systemic burden; shell tuning enhances skin permeation.

Applications: Infectious Diseases, Oncology, and Gene Delivery

Infectious Diseases

Emulsomes address key challenges in treating infectious diseases, particularly intracellular infections. For antileishmanial therapy, where parasites (Leishmania) reside in liver/spleen macrophages, emulsomes’ reticuloendothelial system (RES) targeting and solid lipid core can boost drug accumulation. Their phospholipid shell can protect labile payloads (e.g., antivirals) from enzymatic degradation, and sustained release (24-hour exposure) can ensure consistent antimicrobial activity.

Example:

• Amphotericin B-loaded emulsomes show 3x higher drug levels in infected macrophages vs. free drug, thereby reducing cardiac/kidney toxicity from high-dose antimony derivatives.

Oncology

Hydrophobic chemotypes often suffer from low solubility and early toxicity. Emulsomes can raise apparent solubility, buffer Cmax, and extend exposure. With ligands, they may also sharpen tumor-associated delivery in research models. Moreover, they can evade multidrug resistance by reducing drug efflux from cancer cells.

Example:

• Methotrexate-loaded emulsomes raise apparent solubility by 10,000x, buffer peak concentrations (Cmax) to minimize systemic side effects, and extend tumor exposure.
• Raloxifene-loaded emulsomes with HER2 ligands show 4x higher tumor uptake in MCF-7 breast cancer models, enhancing cytotoxicity.

Gene Delivery

Although classical emulsomes favor hydrophobic drugs, hybrid emulsome designs can carry nucleic acids. For this, you may add cationic lipids or polymer coatings to bind genetic payloads while preserving size and stability.

While classical emulsomes target hydrophobic drugs, hybrid designs (adding cationic lipids such as stearylamine or polymer coatings) enable nucleic acid delivery. Cationic emulsomes can bind negatively charged DNA/RNA via electrostatic interactions, preserving 10-250 nm size and stability.

Example:

• These hybrid emulsomes can deliver siRNA to liver cells with 60% transfection efficiency, making them viable for gene therapies against viral infections or genetic disorders.

Looking for a delivery system for your research?

Contact us at Creative Biolabs to design a delivery system tailored to your research model.

Case Snapshots (Research-Focused)

Case 1: Antileishmanial payload

In rodent studies, emulsomes helped raise liver and spleen drug levels, while limiting systemic peaks. Reports also showed ~12-15% release over 24 h, which fits steady exposure.

Case 2: Hydrophobic oncology agent

Emulsomes improved drug retention and reduced early burst versus simple emulsions, allowing dose flexibility during IV studies.

Case 3: Pulmonary delivery

Aerosolized emulsomes achieved stable particle output and consistent aerodynamic performance, supporting local lung delivery in research settings.

Note:

Data points are representative of research literature and should be verified for your specific system.

Challenges and How to Mitigate Them

For researchers and developers working with emulsome-based delivery systems, navigating common hurdles (from unwanted tissue uptake to scale-up issues) is critical.

Unwanted RES uptake

→ Mitigation: Use PEGylation, ligands, or size tuning.

Batch variability

→ Mitigation: Apply DoE, QbD, and set tight QC specs early.

Hydrophilic cargo limits

→ Mitigation: Consider prodrugs, surface adsorption, or hybrid cores.

Scale-up shear sensitivity

→ Mitigation: Move to inline homogenizers and process analytics.

Oxidative degradation

→ Mitigation: Add antioxidants, choose saturated lipids, and control oxygen/light.

Future Perspectives and Innovations

The next era of emulsome development is defined by science-backed innovations that merge functional design with data-driven optimization, promising to enhance site-specific delivery, extend stability, and streamline formulation workflows for researchers and developers alike.

• Stimuli-responsive shells: pH- or enzyme-triggered layers for controlled site-specific release.
• Lipid-polymer hybrids: Improved stability with tunable drug release.
• Smart ligands and dual targeting: Sequential targeting (organ → cell type) to refine exposure.
• Data-driven formulation: Model-guided DoE to cut cycles and predict release.

How Creative Biolabs Can Help

At Creative Biolabs, we design, build, and analyze emulsomes for research programs across IV, oral, pulmonary, and topical routes. We work from payload assessment to DoE, surface engineering, QC panels, and pilot-scale preparation.

Typical workflow:

1. Target Product Profile — Route, organ focus, release targets, and CMC risks
2. Formulation DoE — Lipid libraries, ratios, and process energy
3. Surface Engineering — PEGylation and/or ligands for precision delivery
4. Analytics — Size/PDI, zeta, EE%, assay, release, and stress stability
5. Scale-Readiness — Process mapping, inline homogenization, lyophilization plan
6. Tech Transfer / Research Supply — Data package, methods, and suggested next steps

Next step:

Share your payload and route goals with our Targeted Delivery team. We will propose a feasibility plan, a DoE grid, and QC endpoints tailored to your needs.

A Practical Checklist for CMC, Analytics, and Quality

Use this QC checklist to keep programs on track:

• Particle size and PDI (DLS)
• Zeta potential (stability signal)
• Entrapment efficiency (EE%) and assay
• In vitro release in biorelevant media
• Stability studies (thermal, oxidative, photostability, agitation)
• Sterility/endotoxin for parenteral research materials
• Aerosol metrics for pulmonary (MMAD, FPF)
• Impurity and oxidation profiles for lipids

Pro tip:

Set acceptance criteria before scale-up. It shortens iteration cycles and reduces rework.

Related Services You May Be Interested in

FAQs

Conclusion

Emulsomes give researchers a practical way to move hydrophobic payloads from concept to consistent exposure. With a solid lipid core and a phospholipid shell, they support controlled release, improve apparent solubility, and naturally reach RES organs when that profile is desired. Because they fit IV, oral, pulmonary, and topical routes, they offer real flexibility across discovery and preclinical workflows.

Key reasons teams choose emulsomes

• Higher loading for hydrophobic compounds
• Smoother, low-burst release profiles
• Tunable surface for RES or non-RES targeting
• Scalable processes with clear QC endpoints

Next Steps with Targeted Delivery

• Share your payload, route, and target organ priorities.
• We design a DoE to balance size, EE%, PDI, and release.
• You receive a data-rich report, a draft CMC spec, and pilot material for RUO studies.

Ready to turn an emulsome idea into a reproducible formulation? Contact Creative Biolabs-Targeted Delivery to get a tailored feasibility plan and timeline.

For Research Use Only. Not for Clinical Use.

References

1. Aldawsari, H. M. et al. "Surface-tailoring of emulsomes for boosting brain delivery of vinpocetine via intranasal route: in vitro optimization and in vivo pharmacokinetic assessment." Drug Delivery 29, 2671–2684 (2022). https://www.tandfonline.com/doi/full/10.1080/10717544.2022.2110996 .
2. Alhakamy, N. A. et al. "Piceatannol-Loaded Emulsomes Exhibit Enhanced Cytostatic and Apoptotic Activities in Colon Cancer Cells." Antioxidants 9, 419 (2020). https://www.mdpi.com/2076-3921/9/5/419 .
3. Singh, S., Khurana, K., Chauhan, S. B. & Singh, I. "Emulsomes: new lipidic carriers for drug delivery with special mention to brain drug transport." Futur J Pharm Sci 9, 78 (2023). https://fjps.springeropen.com/articles/10.1186/s43094-023-00530-z . Distributed under Open Access license CC BY 4.0, without modification.